Benzinga | Jun 17, 2021 04:02PM EDT

Biodesix, Seer Highlight Presentation Of Webinar 'A New Era in Precision Medicine - Uncovering the Depth & Breadth of the Plasma Proteome with Novel Proteomic Technologies'

Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ:SEER), a life sciences company commercializing a disruptive new platform for proteomics, a webinar to present the newest trends in proteomics for biomarker discovery and translational research. The webinar entitled "A New Era in Precision Medicine - Uncovering the Depth & Breadth of the Plasma Proteome with Novel Proteomic Technologies" will be presented by Robert Georgantas, III, PhD, Senior Vice President, Research and Translational Science at Biodesix and Daniel Hornburg, PhD, Principal Scientist from Seer. The webinar is scheduled at 11:00 am ET, Tuesday June 22, 2021 and participants are encouraged to REGISTER HERE.

Proteomics is the next frontier in biomarker and translational research with new emerging technologies that are enabling researchers to see deeper and broader into the plasma proteome than ever before. Biodesix is a recognized leader in profiling patients' immune response to all cancer types using blood-based solutions that combine proteomic and genomic insights with a proprietary AI analytics platform.

The webinar will include an overview of Seer's Proteograph(tm) Product Suite, which uses proprietary engineered nanoparticles to survey plasma proteins, allowing researchers to identify and quantitate proteins across the dynamic range of the proteome. Additionally, learnings will be shared on how the Seer Proteograph Product Suite will help define the biological underpinnings of tests created by Biodesix and how it is being integrated into the Biodesix mass spectrometry-based workflows for biopharmaceutical and academic research.